GoAI
Get started
SUSMED,Inc. logo

SUSMED,Inc.

4263.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥575

−¥1.00 · -0.17%

Aug 24, 11:30 AM JST

4263.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Taro Ueno
Listed since
Dec 24, 2021
Employees
43

Market position

Day range

Current ¥575

52-week range

Current ¥575

Open
¥576
Previous close
¥576
Volume
17.6K
0.1× average
Average volume
178.96K
Average daily volume
Market cap
9.7B JPY
Beta
1.19
Market reference 1
50-day average
¥713.44
-19.40% below average
200-day average
¥864.91
-33.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.91B JPY
P/E (TTM)
-25.32×
P/B (TTM)
2.38×
P/S (TTM)
19.5×
EV / EBITDA
-34.09×
Earnings yield
-2.62%
Free cash flow yield
-3.75%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
96.50%
Operating margin
-66.40%
Net margin
-76.97%
Return on equity
-9.40%
Return on assets
-9.07%
Return on invested capital
-8.11%

Financial health

Debt / equity
0×
Current ratio
27.22×
Altman Z-score
39.83
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends119%37%-45%-127%Gross margin, FY2021: 96.73%Gross margin, FY2022: 98.49%Gross margin, FY2023: 96.58%Gross margin, FY2024: 97.35%Gross margin, FY2025: 96.50%Operating margin, FY2021: -72.32%Operating margin, FY2022: -9.10%Operating margin, FY2023: -106.54%Operating margin, FY2024: -64.68%Operating margin, FY2025: -66.40%Net margin, FY2021: -73.68%Net margin, FY2022: -9.56%Net margin, FY2023: -104.33%Net margin, FY2024: -64.45%Net margin, FY2025: -76.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.73%. Gross margin FY2022 98.49%. Gross margin FY2023 96.58%. Gross margin FY2024 97.35%. Gross margin FY2025 96.50%. Operating margin FY2021 -72.32%. Operating margin FY2022 -9.10%. Operating margin FY2023 -106.54%. Operating margin FY2024 -64.68%. Operating margin FY2025 -66.40%. Net margin FY2021 -73.68%. Net margin FY2022 -9.56%. Net margin FY2023 -104.33%. Net margin FY2024 -64.45%. Net margin FY2025 -76.97%.

Income trends

Revenue

497.21M JPY+7.39%

Operating income

−330.16M JPY-10.24%

Net income

−382.69M JPY-28.25%
Income trends across reported periods621.99M JPY256.65M JPY−108.69M JPY−474.03M JPYRevenue, FY2021: 316.87M JPYRevenue, FY2022: 530.65M JPYRevenue, FY2023: 342.58M JPYRevenue, FY2024: 462.99M JPYRevenue, FY2025: 497.21M JPYOperating income, FY2021: −229.15M JPYOperating income, FY2022: −48.32M JPYOperating income, FY2023: −364.98M JPYOperating income, FY2024: −299.48M JPYOperating income, FY2025: −330.16M JPYNet income, FY2021: −233.48M JPYNet income, FY2022: −50.75M JPYNet income, FY2023: −357.42M JPYNet income, FY2024: −298.4M JPYNet income, FY2025: −382.69M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 316.87M JPY. Revenue FY2022 530.65M JPY. Revenue FY2023 342.58M JPY. Revenue FY2024 462.99M JPY. Revenue FY2025 497.21M JPY. Operating income FY2021 −229.15M JPY. Operating income FY2022 −48.32M JPY. Operating income FY2023 −364.98M JPY. Operating income FY2024 −299.48M JPY. Operating income FY2025 −330.16M JPY. Net income FY2021 −233.48M JPY. Net income FY2022 −50.75M JPY. Net income FY2023 −357.42M JPY. Net income FY2024 −298.4M JPY. Net income FY2025 −382.69M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue497.21M JPY462.99M JPY342.58M JPY530.65M JPY316.87M JPY
Cost of goods sold17.39M JPY12.26M JPY11.73M JPY7.99M JPY10.37M JPY
Gross profit479.82M JPY450.72M JPY330.85M JPY522.67M JPY306.5M JPY
Research and development247.46M JPY273.63M JPY243.35M JPY176.31M JPY226.37M JPY
Selling, general, and administrative562.53M JPY476.57M JPY452.48M JPY394.67M JPY309.28M JPY
Operating expenses809.98M JPY750.2M JPY695.83M JPY570.98M JPY535.65M JPY
Interest income———2K JPY2K JPY
Depreciation and amortization10.17M JPY7.98M JPY5.99M JPY5.55M JPY2.05M JPY
Operating income−330.16M JPY−299.48M JPY−364.98M JPY−48.32M JPY−229.15M JPY
Net income−382.69M JPY−298.4M JPY−357.42M JPY−50.75M JPY−233.48M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-2.97

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates11.573.93-3.7-11.34Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 8, 2024: actual -9.76, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -8.91, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 9.99, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual -9.08, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual -7.17, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -9.03, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual -3.54, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual -2.97, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates372.6M248.41M124.22M27.2KQ4 '24No estimateQ1 '25No estimateQ2 '25BeatQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 8, 2024: actual 32M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual 41M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 345M JPY, estimate 32K JPY, surprise +1078025.00%, Beat. Q3 2025, reported Aug 8, 2025: actual 44M JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual 45M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 46M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual 139M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 267M JPY, estimate —, surprise —, Comparison unavailable.

4263.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥7,008

-0.04%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,799

+0.61%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,990

+0.38%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,392.5

+0.23%

Continue in GoAI

Research 4263.T

research.disclaimer